GnRH agonist (buserelin)-induced in vitro apoptosis in bovine endometrium

Buserelin Inhibits Apoptosis in Male Germ Cells Induced by Busulfan in Mouse Testis

Purpose: The aim of this study was to investigate the effect of buserelin on apoptosis of male germ cells induced by busulfan in adult male mice. Materials and Methods: Male adult NMRI mice were divided into four group of eight each. Group 1 (control) administered PBS for 21 days subcutaneously, group 2 given 0.4 mg buserelin for 21 days subcutaneously, group 3 given single dose of 30 mg/kg bus...

GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET)

Several protocols are actually available for in Vitro Fertilization and Embryo Transfer. The review summarizes the main differences and the clinic characteristics of the protocols in use with GnRH agonists and GnRH antagonists by emphasizing the major outcomes and hormonal changes associated with each protocol. The majority of randomized clinical trials clearly shows that in "in Vitro" Fertiliz...

Human granulosa cells in vitro: influence of GnRH/GnRH-agonist on steroidogenesis and on IVF outcome.

Steroidogenic activities of the granulosa cells (GCs) from 84 IVF trials were evaluated with respect to a set of ovarian stimulation regimens. Oestradiol (E2) synthesis of the GCs in vitro (obtained at oocyte retrieval) was compared to the maximal serum E2 levels of the same patients at induction of ovulation. Three stimulation regimens were employed: human post-menopausal gonadotrophin (hMG) a...

The adjuvant effect of oxytocin on GnRH analogue buserelin.

The mucosa of the nasal cavity has relatively high premeability for peptides. Because of the digestive peptidase activity of the gut, the nasal pathway is currently the route of choice for nonparenteral administration of many peptides including gonadotropin releasing hormone analogues (GnRH-a) . Nevertheless, the transmucosal route of administration may have some problems. Variations exist from...

Microdose GnRH Agonist Flare-Up versus Ultrashort GnRH Agonist Combined with Fixed GnRH Antagonist in Poor Responders of Assisted Reproductive Techniques Cycles